🎉 M&A multiples are live!
Check it out!

Relmada Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Relmada Therapeutics and similar public comparables like Vivoryon Therapeutics, Pharming, and Galapagos.

Relmada Therapeutics Overview

About Relmada Therapeutics

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.


Founded

2012

HQ

United States of America
Employees

17

Website

relmada.com

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

-$34.9M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Relmada Therapeutics Financials

Relmada Therapeutics has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Relmada Therapeutics achieved revenue of n/a and an EBITDA of -$83.9M.

Relmada Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Relmada Therapeutics valuation multiples based on analyst estimates

Relmada Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a n/a XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$104M -$83.9M XXX XXX XXX
EBITDA Margin -Infinity% -Infinity% XXX XXX XXX
Net Profit -$157M -$98.8M XXX XXX XXX
Net Margin -Infinity% -Infinity% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Relmada Therapeutics Stock Performance

As of April 15, 2025, Relmada Therapeutics's stock price is $0.

Relmada Therapeutics has current market cap of $10.0M, and EV of -$34.9M.

See Relmada Therapeutics trading valuation data

Relmada Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$34.9M $10.0M XXX XXX XXX XXX $-2.16

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Relmada Therapeutics Valuation Multiples

As of April 15, 2025, Relmada Therapeutics has market cap of $10.0M and EV of -$34.9M.

Relmada Therapeutics's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Relmada Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Relmada Therapeutics and 10K+ public comps

Relmada Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$34.9M XXX XXX XXX
EV/Revenue n/a XXX XXX XXX
EV/EBITDA 0.4x XXX XXX XXX
P/E -0.1x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 0.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Relmada Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Relmada Therapeutics Valuation Multiples

Relmada Therapeutics's NTM/LTM revenue growth is n/a

Relmada Therapeutics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $4.9M for the same period.

Over next 12 months, Relmada Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Relmada Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Relmada Therapeutics and other 10K+ public comps

Relmada Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth n/a XXX XXX XXX XXX
EBITDA Margin n/a XXX XXX XXX XXX
EBITDA Growth -19% XXX XXX XXX XXX
Rule of 40 (SaaS-only) n/a XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $4.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Relmada Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Relmada Therapeutics M&A and Investment Activity

Relmada Therapeutics acquired  XXX companies to date.

Last acquisition by Relmada Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Relmada Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Relmada Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Relmada Therapeutics

When was Relmada Therapeutics founded? Relmada Therapeutics was founded in 2012.
Where is Relmada Therapeutics headquartered? Relmada Therapeutics is headquartered in United States of America.
How many employees does Relmada Therapeutics have? As of today, Relmada Therapeutics has 17 employees.
Who is the CEO of Relmada Therapeutics? Relmada Therapeutics's CEO is Dr. Sergio Traversa.
Is Relmada Therapeutics publicy listed? Yes, Relmada Therapeutics is a public company listed on NAS.
What is the stock symbol of Relmada Therapeutics? Relmada Therapeutics trades under RLMD ticker.
When did Relmada Therapeutics go public? Relmada Therapeutics went public in 2014.
Who are competitors of Relmada Therapeutics? Similar companies to Relmada Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Relmada Therapeutics? Relmada Therapeutics's current market cap is $10.0M
Is Relmada Therapeutics profitable? Yes, Relmada Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.